Abstract
The objective of this study was to assess the cost-effectiveness of extracorporeal photopheresis (ECP) compared with standard of care (SoC) therapy for the treatment of erythrodermic (stage T4, MO) cutaneous T-cell lymphoma (CTCL) patients, who are refractory to one or more systemic treatments. The perspective of the analysis was that of the Australian health care system.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
